UPLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UPLD is not a good buy right now. Despite being extremely oversold (RSI_6 ~14) and near support (S1 ~1.347 / S2 ~1.293), the dominant trend remains strongly bearish (MACD histogram negative and expanding; SMA_200 > SMA_20 > SMA_5), and the near-term pattern stats also skew slightly negative (60% chance of further downside next day/week). With no Intellectia buy signals today and weak recent fundamentals, an impatient buyer is more likely to catch a falling knife than a clean reversal. Best call: hold off (wait for a reversal/confirmation rather than buying immediately).
Trend is decisively bearish: moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5) confirming a sustained downtrend. Momentum is still weakening: MACD histogram at -0.00667 is below zero and negatively expanding (bearish continuation signal). Mean-reversion setup exists: RSI_6 at 14.447 is deeply oversold, which can support a short-term bounce, but oversold alone is not a buy trigger without reversal confirmation. Key levels: Pivot 1.436; resistance R1 1.525 / R2 1.579; supports S1 1.347 and S2 1.293. Price (~1.32 post-market) is hovering around S1/S2—breakdown risk remains elevated.
Intellectia Proprietary Trading Signals
Technical mean-reversion potential: extremely oversold RSI can spark a short squeeze/bounce if price reclaims the pivot (1.
and holds.
Upcoming earnings (2026-02-12 pre-market) could act as a catalyst if results/guidance surprise positively.
Gross margin improved to 64.31% in 2025/Q3 (+20.82% YoY), showing some efficiency improvement even while revenue fell.
Strong bearish trend and weakening momentum (bearish MA stack; MACD histogram negative and expanding).
Deteriorating top-line and earnings: revenue down sharply YoY and EPS negative, which keeps pressure on valuation/credibility.
Extremely high implied volatility (30D IV ~222%) implies the market expects large swings and reflects elevated downside/tail risk.
No recent news catalysts to justify a near-term re-rating, and pattern-based forward stats lean slightly negative (60% probability of further small declines next day/week).
Latest quarter: 2025/Q3. Revenue fell to $50.53M (‑24.24% YoY), indicating material contraction. Net income was -$2.592M (down -17.43% YoY) and EPS was -$0.09 (down -25% YoY), showing profitability is still negative and worsening on a per-share basis. Bright spot: gross margin rose to 64.31% (+20.82% YoY), suggesting cost structure/product mix improved, but it has not offset the revenue decline.
No analyst rating/price target change data was provided, so the recent trend cannot be verified from this dataset. Practical Wall Street-style framing from the available fundamentals: Pros—improving gross margin and potential for an oversold technical bounce. Cons—sharp revenue decline, ongoing losses, micro-cap scale, and a persistent downtrend with very high implied volatility. Net view based on provided data: cautious/negative.
